From the Research
Serrapeptase may help reduce endometriosis scar tissue, but evidence is limited and it should not replace conventional treatments. The use of serrapeptase for breaking down endometriosis scar tissues is based on its anti-inflammatory and fibrinolytic properties, as reported in a systematic review of the existing evidence 1. However, the evidence supporting its use is insufficient, and more research is needed to fully understand its effects.
Key Considerations
- If considering serrapeptase, typical dosages range from 10,000 to 30,000 SPU (Serratiopeptidase Units) taken 1-3 times daily on an empty stomach.
- Start with a lower dose and gradually increase to minimize digestive side effects.
- The enzyme works by breaking down non-living proteins and reducing inflammation, potentially helping to dissolve fibrin (a component of scar tissue) and decrease inflammatory markers.
- Results vary significantly between individuals, and it may take several weeks or months to notice any effects.
- Common side effects include digestive upset, skin reactions, and increased bleeding risk, so avoid taking it before surgery or if on blood thinners.
Current Management of Endometriosis
Current management of endometriosis involves a combination of medical and surgical treatments, with hormonal therapies being a key component 2. These treatments aim to reduce symptoms, improve quality of life, and prevent disease recurrence. While serrapeptase may be considered as a complementary therapy, it should not replace established treatments that have stronger evidence supporting their effectiveness.
Recommendation
Always consult with your healthcare provider before starting serrapeptase, especially if you have endometriosis, as it should complement rather than replace medical treatments like hormonal therapy or surgery that have stronger evidence supporting their effectiveness for endometriosis management 3, 4, 5. A comprehensive approach to managing endometriosis should prioritize evidence-based treatments and consider individual patient needs and circumstances.